Kalsner S
Br J Pharmacol. 1974 Jul;51(3):427-34. doi: 10.1111/j.1476-5381.1974.tb10678.x.
1 It is proposed that sensitizations of autonomic effectors to agonists by drugs or procedures be considered in two main categories: those involving changes in the effective concentration of agonist at receptors (type I) and those involving changes in the responding tissue beyond the initial combination of agonist and receptors (type II). Type I sensitizations are appropriately described by determining the dose-ratio (horizontal shift of the dose-response curve) and type II sensitizations by assessing the change in the magnitude of the response.2 The inadequacy of the dose-ratio in assessing sensitizations related to an altered physiology of the responding tissue is illustrated by means of hypothetical examples with particular reference to the slopes of dose-response curves and altered maximal responses.3 An evaluation of the enhancement of responses of rabbit aortic strips to agonists by reserpine indicates that it is a type II sensitization. The shifts of dose-response curves to noradrenaline, isoprenaline, normetanephrine and 5-hydroxytryptamine after reserpine-treatment, were described both by the dose-ratio and by the increment in the magnitude of the response at various contraction amplitudes. The dose-ratio varied unpredictably for each agonist depending on the response level selected for comparison and also varied between agonists. However, the mm increment in response magnitude after reserpine approximated a constant value. Responses to potassium which by horizontal procedures were assessed among the least increased, were found to be enhanced the most when considered as a type II sensitization.4 It is concluded that both type I and type II procedures should be applied when dealing with an unidentified sensitization and that the data be critically assessed. The appropriate use of these procedures can aid in identifying and clarifying sensitizations, as well as in elucidating the sequence of steps between receptor activation and response in an effector.
药物或操作引起的自主效应器对激动剂的敏感性可分为两大类:一类涉及受体处激动剂有效浓度的变化(I型),另一类涉及激动剂与受体初始结合后反应组织的变化(II型)。I型敏感性可通过确定剂量比(剂量 - 反应曲线的水平移动)来恰当描述,II型敏感性则通过评估反应幅度的变化来描述。
通过假设示例,特别是参考剂量 - 反应曲线的斜率和最大反应的改变,说明了剂量比在评估与反应组织生理改变相关的敏感性方面的不足。
对利血平增强兔主动脉条对激动剂反应的评估表明,这是一种II型敏感性。利血平处理后,去甲肾上腺素、异丙肾上腺素、去甲变肾上腺素和5 - 羟色胺的剂量 - 反应曲线的移动,既可用剂量比描述,也可用不同收缩幅度下反应幅度的增量描述。每种激动剂的剂量比根据所选比较的反应水平不可预测地变化,且不同激动剂之间也有所不同。然而,利血平处理后反应幅度的毫米增量近似为一个恒定值。通过水平程序评估发现增加最少的对钾的反应,若视为II型敏感性,则增强最为明显。
得出的结论是,在处理不明原因的敏感性时,应同时应用I型和II型程序,并对数据进行严格评估。这些程序的恰当使用有助于识别和阐明敏感性,以及阐明效应器中受体激活与反应之间的步骤顺序。